The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
London, United Kingdom
1-10 Employees
2021
At BioMavericks, our bioinformatics tools help identify these markers from genomic data. Understanding whether a condition is benign or malignant is a critical first step in healthcare decision-making. We strive to provide insights that could be useful for clinicians in planning more tailored treatment options for their patients. Our custom oligos are tailored to offer both timely and cost-effective solutions to validate your findings, ensuring their relevance and usability in real-world scenarios.
+
Featured
AI-Powered Biomarker Discovery
... AI-Powered Biomarker Discovery ...
Planegg, Germany
11-50 Employees
2001
IMGM is your outsourcing partner for demanding projects with a focus on Metagenomics, Biomarker Discovery, Biodistribution and Pharmacogenetics. At IMGM, we combine state-of-the-art technologies with complex data analysis to deliver meaningful results in an easy-to-understand format. Since 2019 IMGM Laboratories is part of Medicover Integrated Clinical Services (MICS), a subdivision of Medicover Diagnostics. IMGM Laboratories is part of Medicover Integrated Clinical Services (former Synevo Central Labs), a specialized business unit within the Medicover Diagnostic Services division with the overarching objective to help bring innovative therapies and diagnostics to the market working with pharmaceuticals. Our goal is to serve the needs of international life science partners wishing to tap into the expertise, professionalism, enthusiasm, and work ethic in Germany and Central Eastern Europe, by providing the utmost quality at a reasonable cost, leveraging flexible and innovative thinking, disciplined management, and significant economies of scale with an attractive cost base. IMGM offers a wide range of services to support you in the discovery of biomarkers. At IMGM, our expert team has long-standing experience in complex assay design and validation, resulting in high-quality data. We offer complete solutions to our customers from pharma, diagnostics, biotech and academia according to your project requirements.
+
Featured
Biomarker Discovery
... IMGM's professional Biomarker Discovery Services include: ...
Mendham, United States
1-10 Employees
2021
Talon Biomarkers offers world-class solutions for precise and powerful biomarker discovery. Fast, complete, and comprehensive data analysis built to precisely identify the cell types driving patient differences. Talon Biomarkers was founded, and is led, by Pratip K.
+
Featured
Home | Talon Biomarkers
... Precise & Powerful Biomarker Discovery ...
+
Featured
EpiSwitch Explorer Array Kit - Whole 3D-genome biomarker discovery – myobdx
... The EpiSwitch® Explorer Array Kit facilitates unbiased 3D genomic biomarker discovery and profiling for academic and clinical R&D. Simultaneously interrogates 1M high-confidence chromosome conformations across the entire human genome. Compatible with Agilent SureScan Microarray Scanners. ...
Aarhus, Denmark
1-10 Employees
2017
Biomcare specializes in profiling and analyzing the microbiome within us, on us and in the world around us. Also, today, we are dependent on the small microbes to survive and function, and at Biomcare we believe that insight into the important role of microorganisms is an avenue for new discoveries and a way forward for our planet. Biomcare believes that an enhanced understanding of both the symbiotic and dysbiotic microbiome will lead to solutions that promote health and wellbeing for both humans and the environment. We used BiomCare to analyse faecal samples collected in a project assessing the role of diet in the development of the infant gut microbiota in Peru. While Biomcare takes great pride in offering sequencing and analysis solutions to our customers, we also conduct our own development projects. Biomcare is working to establish new methods that allow the farmers to evaluate the soil microbiome and make informed discissions on how to improve soil health and increase yield in a sustainable way. We are microbiome experts, and we know the pitfalls and challenges of microbiome research. Biomcare was founded by a team of passionate professionals who aim to fill what we believe is a gap in the field; a company with extensive expertise in handling and analyzing microbiome samples, and who use this knowledge to both service others to harvest the value of microbiome insight, but also take our growing expertise to develop microbiome-based solutions to the danish industry.
+
Featured
Biomarker Discovery
... Biomarker discovery and research. See our products ...
London, United Kingdom
11-50 Employees
1993
Our proteomics expertise provides complementary and enabling content and insight for our customers to develop more effective, time and cost-efficient healthcare solutions. To enable targeted therapeutics by delivering innovative proteomic services.
+
Featured
Biomarker Discovery
... Biomarker Discovery ...
Zurich, Switzerland
1-10 Employees
2022
EVIIVE is disrupting the diagnostic industry with new revolutionary technologies. We are pioneering a cutting-edge platform for liquid biopsy biomarker discovery, along with assay kits tailored for individualized treatment recommendations and disease tracking. EVIIVE is continually building upon its technology, so stay in touch to learn about upgrades and other changes. Eviive is granted a generous fund to further develop extracellular vesicles as a platform to detect immune system defects and accelerate our market entry. EVIIVE wins the UZH-BIOMEDTECH fellowship supported by the WSS foundation. And EVIIVE is offered lab space at IREM-Schlieren supported by the WYSS foundation. Established in 2022, our exceptional team of research specialists has dedicatedly positioned EVIIVE at the pinnacle of the BioMed Tech sector. Our commitment remains unwavering in setting the gold standard in technology, offering comprehensive insights that not only gain industry leader endorsement but also their reliance.
+
Featured
EVIIVE - Novel liquid biopsy
... Novel liquid biopsies biomarkers discovery platform and assay kit provider for personalized treatment guidance and disease progression monitoring. ...
Barcelona, Spain
We are specialists in finding these molecular alterations & in developing diagnostic technology, among others Liquid Biopsy. PANGAEA Oncology is a company focused on Precision Oncology, which offers both patients and pharmaceutical companies different services with the aim of improving the survival of cancer patients, their response to treatments, and their quality of life. The company has two main areas of activity interrelated, such as the clinical care division and the state-of-the-art laboratory that provides services in various areas, including molecular diagnostics as a reference laboratory for both patients and industry, pre-treatment services (clinic to industry), and diagnostic consultancy. PANGAEA ONCOLOGY’s mission is to change the natural history of the disease, improving the survival of cancer patients, through the application of the best professionals and technologies. To position PANGAEA ONCOLOGY as the reference in Europe in Precision Oncology, from patient treatment, the provision of services to the industry, the incorporation of disruptive technology and medical-scientific excellence, and directed towards systems intelligent IT and data exploitation (IA/BIG DATA). PANGAEA ONCOLOGY is a company focused on Precision Oncology, which offers both patients and pharmaceutical companies different services with the aim of improving the survival of cancer patients, their response to treatments, and their quality of life. Position PANGAEA ONCOLOGY as the reference in Southern Europe in Precision Oncology, from patient treatment, the provision of services to the industry, the incorporation of disruptive technology and medical-scientific excellence, and directed towards systems intelligent IT and data exploitation (IA/BIG DATA). Molecular companion diagnostics tests provide essential information that enables doctors to identify those patients that are most likely to benefit from a treatment.
+
Featured
Biomarker Discovery
... Pangaea Oncology - Biomarker Discovery ...
New York, United States
11-50 Employees
2020
Our products make assessments, treatment analysis, and documentation both easier and more accurate, whether used in the background during clinical encounters or interactively through our digital health assistant.
+
Featured
Deliberate.ai | Multimodal assessment of psychiatric and neurological health
... Deliberate's Biomarker Discovery and Validation Platform, Multitude™, provides state-of-the-art AI and machine learning techniques to better understand, measure, and develop predictions for psychiatric and neurologic disorders. ...
Frederick, United States
1-10 Employees
2012
We are a sample analysis and research augmentation service company, utilizing state-of-the-art instruments and technologies to provide omics solutions. Poochon’s state-of-the-art facility also supports DNA sequencing, microbial identification, and antibody sequencing. Years of highly focused bioanalysis practice brought Poochon unparalleled expertise in vaccines and antibody therapeutics. Founders of Poochon Scientific came with tens of years of experience in protein biochemistry, molecular and cellular biology, mass spectrometry instrumentation, bioinformatics, biopharmaceutical development, FDA regulatory compliance and more. Today, Poochon is the best choice of ‘omics’ services in Greater Washington DC area, serving clients nationwide and internationally, from biotech and biopharma to research institutions and government agencies. Poochon is thriving by delivering the best service in terms of data quality, speed, and cost efficiency for our clients. Our free consultations and adherence to standardized sample preparation protocols ensure delivery of reliable and high-quality data in succinct reports. Poochon offers a full range of proteomics services which include sample preparation, sample analysis, data reporting and interpretation through a unique understanding of protein analysis, global protein profiling and biological pathway analysis.
+
Featured
Biomarker Discovery | Poochon Scientific
... Biomarker Discovery | Poochon ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Biomarker Discovery
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 88 |
| Amount of suitable service providers | 80 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1993 |
| Youngest suiting company | 2022 |
20%
40%
60%
80%
Biomarker discovery refers to the process of identifying biological markers (biomarkers) within the body that are indicative of a particular disease state, physiological state, or response to a treatment. This process typically involves comprehensive research and analysis of genes, proteins, and other molecules to find reliable indicators of health or disease. Biomarkers can range from simple molecules such as glucose found in blood, to complex gene expressions and alterations in cellular structures. The significance of biomarker discovery lies in its potential to revolutionize the medical field, providing tools for early detection of diseases, improved diagnostic processes, and the development of personalized medicine. By enabling healthcare professionals to identify diseases in their nascent stages, biomarker discovery paves the way for timely and more effective interventions. Furthermore, it facilitates the monitoring of disease progression and response to treatment, allowing for adjustments in therapy to optimize patient outcomes. The impact of biomarker discovery extends beyond individual patient care to influence drug development and therapeutic strategies, offering a pathway to more targeted and efficient healthcare solutions. Through the precise identification and validation of biomarkers, researchers and clinicians can significantly enhance the accuracy of disease diagnosis, prognosis, and therapeutic effectiveness, ultimately contributing to improved health outcomes and quality of life for patients.
1. Enhanced Diagnostic Precision
Biomarker discovery allows for the identification of specific biological markers in the body, leading to more accurate and early diagnosis of diseases. This precision is crucial for conditions where early detection significantly improves treatment outcomes.
2. Personalized Treatment Plans
By understanding the unique biomarkers present in an individual, healthcare providers can tailor treatments to the patient's specific needs. This individualized approach not only improves the effectiveness of treatments but also minimizes potential side effects, enhancing patient care.
3. Improved Drug Development
The identification of new biomarkers can significantly streamline the drug development process. By targeting these specific markers, pharmaceutical companies can develop more effective drugs, reduce the time and cost associated with clinical trials, and bring treatments to market more quickly.
4. Non-Invasive Testing Methods
Many biomarker tests are non-invasive, requiring only blood samples or other easily obtainable biological materials. This aspect greatly reduces the risk and discomfort associated with traditional diagnostic methods, improving patient compliance and overall experience.
While evaluating the different suppliers make sure to check the following criteria:
1. Technology and Equipment
Ensure the supplier has access to the latest technology and high-quality equipment necessary for comprehensive biomarker discovery, including next-generation sequencing and mass spectrometry.
2. Experience and Expertise
Look for suppliers with a solid track record and expertise in your specific area of interest, be it oncology, neurology, or another field, to ensure they can provide valuable insights and high-quality results.
3. Quality Assurance and Certifications
Check for certifications such as ISO or CAP, which indicate the supplier adheres to strict quality standards in their processes and outputs.
4. Data Analysis and Reporting
Assess the supplier’s capability in advanced data analysis and their ability to provide comprehensive, understandable reports that meet your project needs.
5. Cost-effectiveness and Timeliness
Consider the balance between cost and value; ensure the supplier can deliver high-quality results within your budget and timelines.
6. Client Support and Communication
Good communication is crucial. Choose a supplier that offers excellent client support, maintains transparency throughout the project, and is responsive to your inquiries and updates.
Biomarker discovery has become a cornerstone in the pharmaceutical industry, enabling companies to streamline drug development processes. Through identifying specific biological markers, pharmaceutical firms can more efficiently determine drug efficacy and safety, reducing the time and cost associated with bringing new medications to market. This precision accelerates the pipeline from discovery to approval, ensuring that safer, more effective treatments reach patients faster. In the realm of personalized medicine, biomarker discovery plays a pivotal role. Healthcare companies leverage these biological indicators to tailor treatments to individual patients, enhancing therapeutic outcomes. By understanding the genetic and molecular profiles that biomarkers reveal, medical practitioners can prescribe more effective drugs with fewer side effects, thereby improving patient care and satisfaction. The agricultural sector also benefits from biomarker discovery, particularly in crop improvement and protection. By identifying biomarkers related to stress resistance and nutrient utilization, agribusinesses can develop crop varieties that withstand environmental challenges and require fewer resources. This not only boosts yield and reduces costs but also contributes to sustainable farming practices, addressing global food security concerns. In environmental monitoring, biomarkers serve as early indicators of ecosystem health. Companies specializing in environmental services use biomarker discovery to detect contaminants and assess the impact of industrial activities on natural habitats. This facilitates more responsible resource management and helps in the formulation of strategies to mitigate environmental damage, ensuring compliance with regulatory standards and conservation efforts.
Biomarker discovery currently finds itself at varying Technology Readiness Levels (TRLs), primarily between TRL 4 and TRL 6, depending on the specific biomarker and application in question. This range is attributed to the stage of validation and the transition from controlled environments to real-world application. At TRL 4, biomarker discovery involves the successful integration of technologies in a lab setting, where controlled experiments validate the capability of these biomarkers to indicate specific diseases or physiological states. Progressing to TRL 5 and 6, these discoveries undergo further testing in relevant environments, often involving larger sample sizes and more complex biological matrices. The reason for this specific placement within the TRL spectrum lies in the inherent challenges of biomarker discovery, including the need for high specificity and sensitivity, the complexity of human biology, and the rigorous validation processes required to ensure that a biomarker can reliably predict or diagnose conditions. Additionally, the process of translating these discoveries from bench to bedside is fraught with technological hurdles, such as the development of cost-effective, robust, and user-friendly detection platforms. These stages reflect ongoing efforts to refine these technologies and validate their efficacy in broader, more variable populations, which is crucial for their eventual widespread clinical use.
In the Short-Term, advancements in biomarker discovery are expected to be driven by the integration of artificial intelligence (AI) and machine learning (ML) algorithms. These technologies will enhance the speed and accuracy of identifying potential biomarkers in genetic and proteomic data. The immediate focus will be on improving diagnostic methods for diseases such as cancer and Alzheimer's, facilitating early detection and personalized treatment plans based on individual biomarker profiles. The Mid-Term phase will likely witness the evolution of high-throughput technologies and next-generation sequencing, enabling researchers to explore a broader range of biomarkers, including those related to lifestyle and environmental factors. This period will see a significant shift towards the discovery of non-invasive biomarkers, such as those found in blood or saliva, making the diagnostic process less intrusive for patients. These advancements will pave the way for more comprehensive health monitoring and disease prevention strategies. In the Long-Term, the focus will shift towards the integration of biomarker discovery with personalized medicine, where treatments will be tailored not just to the disease but to the patient's unique biomarker profile. This era will likely see the development of smart, nanotechnology-based delivery systems that can target specific biomarkers, offering highly effective and individualized therapies with minimal side effects. The ultimate goal will be to move beyond disease treatment to disease prevention, using biomarkers to identify and mitigate risk factors before they manifest into disease.
Some interesting questions that has been asked about the results you have just received for Biomarker Discovery
What are related technologies to Biomarker Discovery?
Based on our calculations related technologies to Biomarker Discovery are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Biomarker Discovery?
Start-Ups who are working in Biomarker Discovery are BioMavericks
,
Talon Biomarkers,
Eviive,
Deliberate AIWhich industries are mostly working on Biomarker Discovery?
The most represented industries which are working in Biomarker Discovery are Biotechnology, Health Care, Science and Engineering, Professional Services, Data and Analytics
How does ensun find these Biomarker Discovery Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
